Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid
| Autor: | P. Peña, Á. Campos, G. Royo, P. Berdonces, A. Pinedo, José Campos, M. José Gastañares, E. Garduño, C. Fuster, O. del Valle, Mar Olga Pérez-Moreno, M. A. Mantecón-Vallejo, L. Marco, Edurne Lázaro, N. Gonzalo, Fernando Baquero, J. Rodríguez-Hernández, A. Yagüe, Adriana Ortega, S. Sabater, V. García-López, R. Moreno, C. Miranda, M. F. Brezmes, E. Ojeda, M. A. Miguel, L. Martínez, D. Fontanals, M. T. Pérez-Pomata, Silvia García-Cobos, A. González, I. Cuesta, B. Fernández, P. Álvarez, I. Buj, M. García-Campello, M. D. Crespo, P. López, Carmen Aspiroz, A. Sierra, C. Freyre, M. J. Revillo, Francisco J. de Abajo, Ana María Fleites, F. J. Vasallo-Vidal, V. Gallardo, Oscar Cuevas, C. Raya, V. Pulian, E Martin, S. Bernal, Jesús Oteo, Jorge Calvo, E. Loza, C. Aldea, C. Amores, Belén Aracil, M. J. González-Abad, J. Lite, I. Wilhemi, M. T. Cabezas, J. C. Alados, N. Montiel, María Cruz Rodríguez, J. J. Palomar, J. A. Lepe, S. García de Cruz, A. Tinajas, Alberto Delgado-Iribarren, M. D. Rojo, M. Menéndez-Rivas, P. Teno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
Ofloxacin Moxifloxacin Drug Resistance Bacteremia Drug resistance Levofloxacin 80 and over Pharmacology (medical) Quinolines/therapeutic use Escherichia coli Infections Aged 80 and over Escherichia coli/drug effects Drug Utilization/statistics & numerical data Bacterial Middle Aged Hospitals Bacteremia/microbiology Ciprofloxacin Infectious Diseases Quinolines Female Fluoroquinolones medicine.drug Escherichia coli Infections/microbiology Microbiology (medical) Adult Adolescent Biology Amoxicillin-Potassium Clavulanate Combination Microbiology Young Adult Antibiotic resistance Clavulanic acid Drug Resistance Bacterial Escherichia coli medicine Humans Aged Pharmacology Aza Compounds Amoxicillin/clavulanic acid Amoxicillin-Potassium Clavulanate Combination/therapeutic use Amoxicillin biochemical phenomena metabolism and nutrition bacterial infections and mycoses Fluoroquinolones/therapeutic use Drug Utilization Spain Aza Compounds/therapeutic use Ofloxacin/therapeutic use |
| Zdroj: | Journal of Antimicrobial Chemotherapy, 66(3), 664-669. Oxford University Press |
| ISSN: | 0305-7453 |
| Popis: | OBJECTIVES: To determine trends in ciprofloxacin resistance and co-resistance to other antibiotic classes in blood isolates of Escherichia coli, and to investigate if there is an ecological relationship to the community use of fluoroquinolones and other antibiotics.METHODS: Forty-two Spanish hospitals of the European Antimicrobial Resistance Surveillance Network collected ciprofloxacin and other antibiotic susceptibility data for non-duplicate consecutive E. coli isolates from patients with bacteraemia between 2001 and 2009. The nationwide ambulatory use of antibiotics between 1997 and 2008 was determined by WHO methods, and the co-evolution of both parameters was further analysed.RESULTS: Of the 28 307 E. coli blood isolates, 27.9% were ciprofloxacin non-susceptible (CIPNS), increasing from 17.6% in 2001 to 32.7% in 2009. A continuous increase was observed between CIPNS and other resistances, including cephalosporin resistance due to the production of extended-spectrum β-lactamases (ESBLs) and non-susceptibility to both amoxicillin/clavulanic acid and tobramycin. Although the total use of antibiotics did not increase, community use of levofloxacin, moxifloxacin and amoxicillin/clavulanic acid increased by 307.2%, 62.6% and 70.1%, respectively. Yearly rates of CIPNS E. coli strongly correlated with the use of levofloxacin, moxifloxacin and amoxicillin/clavulanic acid (r(2 )> 0.80; P CONCLUSIONS: The rapid increase in CIPNS E. coli causing bacteraemia was closely related to the increase in resistance to amoxicillin/clavulanic acid, production of ESBLs and resistance to aminoglycosides. Community use of fluoroquinolones (mainly moxifloxacin and levofloxacin) and of amoxicillin/clavulanic acid represents a significant driver in the progression of fluoroquinolone resistance in bacteraemic E. coli. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|